-
"Hot" the "cold" tumor!
Time of Update: 2021-12-05
Oncolytic virus "arming" strategy Oncolytic viruses work through dual mechanisms: 1) selectively replicate and lyse infected cancer cells; 2) induce host anti-tumor immunity .
-
When does lung cancer irAE occur?
Time of Update: 2021-12-05
During the treatment process, timely and meticulous monitoring, including patient symptoms, signs, hematological indicators and imaging changes, can be used to identify and predict the occurrence of severe irAE as soon as possible, so as to improve the patient's prognosis .
-
Hundred cases of excellent brain metastases from advanced lung cancer-macromolecular anti-angiogenic drugs combined with chemotherapy bring tumor regression
Time of Update: 2021-12-05
Immediately given oral erlotinib (150mg/day) treatment, the headache symptoms disappeared after 1 month, and the imaging review showed that the lung tumor lesions and intracranial metastases were reduced.
-
CCSC: Good news spreads frequently, long-term benefit, CAR-T curative effect sees the truth
Time of Update: 2021-12-05
On June 22, 2021, Yikaida® (Akilunza injection) was formally approved by the National Medical Products Administration (NMPA), becoming China’s first CAR-T therapy drug targeting CD19 for the treatment of previously accepted drugs Adult patients with relapsed or refractory large B-cell lymphoma (R/R LBCL) after second-line or above systemic treatment have brought new treatment options for R/R LBCL .
-
Big coffee explores "Ao" anti-CD20 monoclonal antibody "Big Brother" starts well, "new generation" high starting point helps lymphoma diagnosis and treatment
Time of Update: 2021-12-05
Especially for B-cell non-Hodgkin's lymphoma (B-NHL), since the advent of the first generation of anti-CD20 monoclonal antibody-rituximab, the clinical treatment outcome of most patients has been significantly improved.
-
[The Lancet] Breakthrough!
Time of Update: 2021-12-05
Recently, researchers published the results of this new study in "The Lancet Oncology" and published an article entitled "Dabrafenib plus trametinib in patients with BRAFV600E-mutant low-grade and high-grade glioma (ROAR): a multicentre , open-label, single-arm, phase 2, basket trial" article: This combination of drugs blocks overactive cell growth signaling pathways.
-
Myeloma New Horizons Multiple Myeloma Renal Insufficiency: A systematic review and meta-analysis of all randomized trials from 2005 to 2019
Time of Update: 2021-12-05
In order to assess the proportion and prognosis of multiple myeloma (MM) patients with renal insufficiency (RI), as well as the impact on the treatment effect, a systematic review and meta-analysis published in Leuk Lymphoma in 2021 on all patients from 2005 to 2019 MM-related randomized controlled trials (RCT) are analyzed to evaluate the prevalence, inclusion criteria and results of renal insufficiency in patients with MM .
-
100% objective relief?
Time of Update: 2021-12-05
In May of this year, the MD Anderson Cancer Center of the University of Texas in the United States published the latest research results in Clinical Cancer Research of the American Association for Cancer Research, showing that cytokine-activated donor cord blood-derived natural killer (cbNK) cells combine to target CD16a and The CD30 research bispecific antibody AFM13 has strong anti-tumor activity against CD30+ lymphoma cells .
-
Teriplizumab has a new indication, osimertinib + bevacizumab failed to bring benefits to drug-resistant patients
Time of Update: 2021-12-05
(If you need the original text of the literature, you can add the editor WeChat yxj_oncology to obtain it) Key points: Annals of Oncology: Osimertinib combined with bevacizumab failed to give epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI) ) Treatment failure patients bring survival benefits NEJM: Hypoxia-inducible factor-2α (HIF-2α) inhibitor Belzutifan in the treatment of Von Hippel-Lindau (VHL) syndrome-associated renal cell carcinoma (RCC) has a gratifying effect.
-
CheckMate-067 research data update, O+Y program enables patients with advanced melanoma to obtain 6-year OS!
Time of Update: 2021-12-05
New drug: PD-L1/CTLA4 double antibody + chemotherapy for the treatment of advanced pancreatic cancer was approved Phase III clinical new drug: Vometinib is planned to be included in breakthrough therapy 01 The Lancet Oncology: Dabrafenib combined with trametinib may improve glioma Current status of treatment At present, there is still an urgent need for treatments that can improve the prognosis of patients with low- or high-grade gliomas .
-
A major outbreak of first-line immunization programs for advanced non-small cell lung cancer: single-agent, combined, and dual-immune programs each show their potential for lung cancer immunity review in 2021
Time of Update: 2021-12-05
In the results of the previously published Phase III randomized controlled study of CheckMate 9LA, for metastatic NSCLC without EGFR and ALK gene mutations, the first-line use of nivolumab (NIVO) + ipilimumab (IPI) Compared with the standard 4 cycles of chemotherapy, 2 cycles of chemotherapy significantly improved the patient's overall survival (OS), progression-free survival (PFS) and objective response rate (ORR) .
-
Verbutuximab is used as a single agent to treat R/R cHL, and new evidence-based evidence has been released!
Time of Update: 2021-12-05
A total of 32 reports were included in the system review to report treatment mode, overall response rate (ORR), CR rate, progression-free survival (PFS), overall survival (OS), and observational properties of adverse events The study (Table 1) contains data on the effectiveness or safety of BV in the treatment of R/R cHL in the real world environment for more than ten years (1996-2019) .
-
The world's first subcutaneous injection of PD-L1 drug is here!
Time of Update: 2021-12-05
As an innovative drug, Envolimab is in II Shortly after the release of the data of the first phase of the study, it was quickly included in the priority review and was approved recently, officially entering the field of advanced solid tumors in China’s MSI-H/dMMR, bringing new treatment options and survival hopes to patients, and also leading Chinese tumors Immunotherapy is moving further towards the era of precision treatment .
-
Some drug-resistant leukemias have new treatment options!
Time of Update: 2021-12-05
Screenshot source: NMPA official website According to the information on the NMPA official website, oribatinib is the first drug approved for the indication of chronic myeloid leukemia with T315I mutation in mainland China, providing effective treatment for patients who are resistant to T315I mutation Treatment methods .
-
The progress of new drugs, the first three-generation Gleevec in China!
Time of Update: 2021-12-05
Yesterday, the latest NMPA approval showed that the third-generation BCR-ABL inhibitor Orebatinib (Nelic®) of Ascent Pharmaceuticals was approved to be marketed for the treatment of resistance to any tyrosine kinase inhibitor (TKI).
CML patients with T315I mutations are resistant to all current first- and second-generation BCR-ABL inhibitors.
-
what reason?
Time of Update: 2021-12-05
02 We have compiled a study of the East China population in Frontiers in Genetics [1], which completed the data analysis of MSI and clinicopathological characteristics of 2356 patients with colorectal cancer .
-
[Lymphoma Microclass 2021ASH First Look] Long-term follow-up results of iFCR treatment of young newly-treated CLL, I or IR treatment of TP53 abnormal CLL
Time of Update: 2021-12-05
The secondary endpoints were to evaluate the response rate, PFS/OS, BM-uMRD rate, and safety/tolerability after 2 years of maintenance treatment with ibrutinib .
Abstract 3734: Long-term follow-up results of ibrutinib monotherapy or combined with rituximab in the treatment of CLL patients with newly treated and relapsed/refractory TP53 abnormalities.
-
Clin Cancer Res: Comparison of treatment-free survival (TFS) between nivolumab + ipilimumab and sunitinib in patients with advanced renal cell carcinoma (aRCC): results from Check-Mate 214
Time of Update: 2021-12-04
Among 847 aRCC patients with intermediate or poor prognostic risk of IMDC, the 42-month OS rates in the nivolumab + ipilimumab group and sunitinib group were 52% and 39%, respectively .
-
Eur J Cancer: The effect of DNA damage repair status on the activity of cabazitaxel in the treatment of metastatic castration-resistant prostate cancer
Time of Update: 2021-12-04
Previous studies have shown that Cabazitaxel can improve the overall survival (OS) of patients with metastatic castration-resistant prostate cancer (mCRPC) after treatment failure with abiraterone/enzalutamide and docetaxel, although The benefits of the presence of DNA damage repair (DDR) defects are unclear .
-
Aliment Pharmacol Ther: Serum GDF15 can predict the risk of liver cancer after hepatitis C virus is eliminated
Time of Update: 2021-12-04
The GDF15, AFP and FIB-4 index scores can predict the risk of liver cancer after hepatitis C is cured .
The GDF15, AFP and FIB-4 index scores can predict the risk of liver cancer after hepatitis C is cured .
